All three trials in the Company’s registrational ECLIPSE program for chronic hepatitis delta (CHD) have now been initiated.

SAN FRANCISCO, August 06, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in ECLIPSE 3. All three trials in the Company’s registrational ...

ECLIPSE 2 is one of three trials in Vir Biotechnology’s registrational ECLIPSE program for CHD, which was initiated in March 2025.

ECLIPSE is a registrational program to evaluate the safety and efficacy of tobevibart in combination with elebsiran in patients with chronic hepatitis delta (CHD).

Florida Governor Ron DeSantis shared some sharp criticism of the H-1B visa program, even as Trump maintains legal immigration levels.

New quantum computing system allows multiple users to run programs simultaneously using virtual machines.

WASHINGTON—The Trump administration is blocking funding for a swath of public-health programs run by the Centers for Disease Control and Prevention, the latest flashpoint in a push by the White ...

Examining Dabo Swinney's 'first 16-0 team' College Football Playoff prediction: Can Clemson run the table? Dabo Swinney has never had a confidence issue ...

Merkley introduced a bill to release all Epstein investigation files, saying anyone involved in abusing minors “should be held accountable.” ...